Entry |
|
Name |
Vatalanib (USAN/INN) |
Formula |
C20H15ClN4
|
Exact mass |
346.0985
|
Mol weight |
346.81
|
Structure |

|
Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
Efficacy |
Antineoplastic, Angiogenesis inhibitor, Receptor tyrosine kinase inhibitor |
Target |
|
Pathway |
|
Interaction |
|
Structure map |
map07045 | Antineoplastics - protein kinase inhibitors |
|
Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D06285 Vatalanib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRB
D06285 Vatalanib (USAN/INN)
KIT (CD117)
D06285 Vatalanib (USAN/INN)
VEGFR family
VEGFR1 (FLT1)
D06285 Vatalanib (USAN/INN)
VEGFR2 (KDR)
D06285 Vatalanib (USAN/INN)
VEGFR3 (FLT4)
D06285 Vatalanib (USAN/INN)
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 25
1 C8x C 20.3121 -19.0002
2 C8x C 20.3121 -20.4008
3 C8x C 21.5280 -21.1011
4 C8x C 21.5280 -18.3000
5 C8y C 22.7367 -19.0002
6 C8y C 22.7308 -20.4008
7 C8y C 23.9407 -21.1061
8 N5x N 25.1566 -20.4111
9 N5x N 25.1625 -19.0106
10 C8y C 23.9526 -18.3053
11 N1b N 23.9585 -16.9047
12 C8y C 25.1746 -16.2095
13 C8x C 26.4164 -16.9331
14 C8x C 27.6316 -16.2380
15 C8y C 27.6373 -14.8380
16 C8x C 26.3954 -14.1144
17 C8x C 25.1802 -14.8095
18 X Cl 28.8612 -14.1378
19 C1b C 23.9346 -22.5400
20 C8y C 25.1481 -23.2475
21 C8x C 25.1421 -24.6399
22 C8x C 26.3515 -25.3452
23 N5x N 27.5669 -24.6504
24 C8x C 27.5729 -23.2580
25 C8x C 26.3635 -22.5527
BOND 28
1 1 2 2
2 2 3 1
3 3 6 2
4 5 4 2
5 5 6 1
6 6 7 1
7 7 8 2
8 8 9 1
9 9 10 2
10 10 5 1
11 4 1 1
12 10 11 1
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 12 17 1
20 15 18 1
21 7 19 1
22 19 20 1
23 20 21 2
24 21 22 1
25 22 23 2
26 23 24 1
27 24 25 2
28 20 25 1
|